Market News & Trends
Concert Pharmaceuticals Receives $50-Million Payment From Auspex Pharmaceuticals
Concert Pharmaceuticals, Inc. recently announced that it has received a payment of $50.2 million from Auspex Pharmaceuticals, Inc. The payment is pursuant to a September…
Immune Pharmaceuticals Expands Immuno-Dermatology Development Portfolio
Immune Pharmaceuticals Inc. recently announced it has entered into a binding Memorandum of Understanding with Yissum, the Technology Transfer Company of the Hebrew University of…
FDA Awards Isarna Orphan Drug Designation
Isarna Therapeutics recently announced that the Food and Drug Administration (FDA) has granted orphan drug designation for ISTH0036, a locked nucleic acid-modified antisense oligonucleotide, for…
Mylan Launches First Bioequivalent Alternative to Combination Asthma Therapy
Mylan N.V. recently announced it has launched the first bioequivalent alternative to GlaxoSmithKline’s Seretide Evohaler (salmeterol xinafoate/fluticasone propionate) under the brand name Sirdupla in the…
Melinta Therapeutics Announces Financing to Fund Completion of Final Phase III Study
Melinta Therapeutics recently announced the successful completion of a $67-million Series 4 equity financing. Malin Corporation plc led the round and was joined by other…
Vericel Announces Plan to Submit Biologics License Application to the FDA
Vericel Corporation recently announced that following discussions with the US Food and Drug Administration (FDA), the company plans to submit a Biologics License Application (BLA)…
Trehalose: A Powerful Excipient in the Formulation Toolbox
By: Ben Nelson, PhD, and Chris Wilcox (inquiries to: cs@pfanstiehl.com) Trehalose is a non-reducing disaccharide consisting of two glucose molecules linked by an α,α–1,1…
BIND Therapeutics & Macrophage Therapeutics Announce Collaboration to Engineer CD206 Targeted Accurin Nanoparticle Using Manocept Macrophage Targeting Platform
BIND Therapeutics, Inc. and Macrophage Therapeutics recently announced they have entered into a research collaboration to engineer Accurins with the Manocept™ targeting platform that enables…
Targeted Therapeutics & Nanoparticles
A key objective of pharmaceutical and biopharmaceutical development is to increase product therapeutic specificity and safety. Some of the recent exciting developments have obviously been…
The CDMO Market: Implications of Patheon's IPO
By: Patricia Van Arnum, DCAT Editorial Director, posted Tue, Jun 09, 2015 04:42 AM Patheon's announcement this week that it plans to file for an initial public…
SGS Life Science Services Opens New Lab; Broadens Biologics Capabilities
SGS Life Science Services, the leading analytical and bioanalytical contract solutions provider, today announced the planned opening of its new bio/pharmaceutical quality control laboratory at…
Halozyme Enters Lucrative Global Collaboration & Licensing Agreement
Halozyme Therapeutics, Inc. recently announced a global collaboration and license agreement with AbbVie to develop and commercialize products combining proprietary AbbVie compounds with Halozyme's ENHANZE…
Recipharm Signs Partnership Agreement With Follicum
Recipharm recently announced it has signed a partnership agreement with Follicum AB in preparation for a clinical trial of the drug candidate FOL-005. Recipharm has…
EMD Millipore Introduces Compaction Technology to Improve Solubility
EMD Millipore, the Life Science business of Merck KGaA of Darmstadt, Germany, recently introduced a new technology that compacts dry powder cell culture media into…
Unchained Labs Announces Major Acquisition; Second of the Year
Unchained Labs recently announced the acquisition of AVIA Biosystems, the developer of the Isothermal Chemical Denaturation (ICD) system for measuring biologic stability. This is the…
Oxis Biotech Files US Patent Application Covering Additional Analogs
Oxis Biotech, Inc. recently announced it has filed a US patent application covering additional analogs of the company's lead compound, OXS-4235, a potent p62/Sequestosome 1…
Egalet Announces Top-Line Study Results
Egalet Corporation recently announced top-line results from a randomized, four-way crossover alcohol-interaction study in healthy male and female moderate drinkers with Egalet-002, an abuse-deterrent, extended-release,…
Glaucoma Treatment Market Value Will Grow Moderately to $3 Billion
The treatment market for glaucoma will rise in value from $2.4 billion in 2013 to approximately $3 billion by 2023 across the seven major markets…
Drug Abuse Triggers Regulations to Push the Development of Tamper-Resistant Opioid Formulations for Pain Management
The pain market is currently dominated by opioid analgesics, which have well-known side effects, such as addiction and constipation. However, a $10-billion market exists for…
Mapi Pharma Closes $10-Million Investment
Mapi Pharma Ltd. Recently announced that Shavit Capital has led an investment round of $10 million in the company in a Series A financing round…
